Physician profile
Michael Burrow
NPI 1124480868
$1,170.83
in general payments reported to CMS, 2019-2025
16 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $54.65 · 2021: $197 · 2022: $128 · 2023: $159 · 2024: $71.69 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $378.56 | 2019-2025 | Clareon, Argos, Precision 1 |
| Novartis Pharmaceuticals Corporation | $169.39 | 2020-2023 | |
| Allergan, INC. | $153.20 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.79 | 2019 | |
| Bausch & Lomb Americas INC. | $66.03 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $37.90 | 2024-2025 | |
| Sight Sciences, INC. | $36.72 | 2019-2024 | Omni Surgical System |
| Dompe US, INC. | $35.55 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $33.19 | 2021 | |
| Astellas Pharma US INC | $32.37 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $31.32 | 2022-2024 | |
| Recordati_rare_diseases_inc. | $27.06 | 2023 | Cystadrops |
| Neurotech Pharmaceuticals, INC. | $24.50 | 2025 | |
| Horizon Therapeutics Plc | $19.58 | 2023 | Tepezza |
| Ivantis, INC | $14.13 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $13.54 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Burrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.